The Sickle Cell Clinical Trials Network: One Year In
The Hematologist Editor-in-Chief, Dr. Laura Michaelis, spoke with Drs. Charles Abrams and Sophie Lanzkron about a groundbreaking ASH initiative started approximate
Is Double-hit Diffuse Large B-cell Lymphoma More Common Than We Think?
Dr. Kahl studies the biologic underpinnings of a new entity that does not meet the classical definition of double-hit (DH) DLBCL but has gene expression signatures and clin
In her last President's Column, Dr. Alexis Thompson looks back on a year full of change and advancement through a series of initiatives and provides a glimpse of what's to come in 2019 and beyond.
Dr. Thompson shares her experience traveling to Ghana as part of ASH's efforts to reduce SCD-related mortality by promoting newborn screening and early intervention in sub-Saharan African countries.
Dr. Thompson discusses ASH's advocacy efforts in support of programs and policies that enable the Society to deliver change to patients and their families worldwide.
Dr. Thompson discusses ASH sickle cell disease (SCD) initiatives as part of ASH's mission to help those who treat SCD patients provide quality care, continue their professional development, and enhance their knowledge and expertise.
Dr. Thompson discusses the many global initiatives that define ASH's international efforts as well as the Society's global reach as a powerful reflection of it's mission.
In her first President's Column, Dr. Alexis Thompson ushers in 2018 with a discussion of annual meeting media highlights.
Drs. Badawy, Liem, and Thompson discuss several benefits, risks, and limitations of using health-related apps, focusing on hematology and oncology apps. They present a thorough study that includes recommendations of some of the best apps available, and a discussion of clinical benefits, cost-effectiveness, potential risks, and even legal concerns.
Dr. Alexis Thompson makes a thorough assessment of the latest clinical practice guidelines for sickle cell disease.
In June 2011, ASH hosted a workshop aimed at determining whether, based on available evidence, individuals with sickle cell trait are at increased risk for exertion- or heat-related illness or sudden death. The workshop also sought to determine if there was evidence-based support for requiring adult screening for sickle cell trait as a prerequisite for participation in athletics.
July-August 2019Volume 16, Issue 4
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology